34 days to first decision for reviewed manuscripts only
27 days to first decision for all manuscripts
56 days from submission to acceptance
12 days from acceptance to publication
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
Patients with Myelodysplastic Syndromes (MDS) and secondary Acute Myeloid Leukemia (sAML) have a very poor prognosis after failure of hypomethylating agents (HMA). Stem cell transplantation is the only effecti...
Citation: Experimental Hematology & Oncology 2019 8:9